Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data

The Lancet

Volumn 381, Issue 9880, 2013, Pages 1827-1834

  Cuzick, Jack ^a   Sestak, Ivana ^a   Bonanni, Bernardo ^b   Costantino, Joseph P ^c   Cummings, Steve ^d   DeCensi, Andrea ^e   Dowsett, Mitch ^f   Forbes, John F ^g   Ford, Leslie ^h   LaCroix, Andrea Z ⁱ   Mershon, John ^j   Mitlak, Bruce H ^k   Powles, Trevor ^l   Veronesi, Umberto ^b   Vogel, Victor ^m   Wickerham, D Lawrence ⁿ  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NSABP Foundation Inc   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e GALLIERA HOSPITAL   (Italy)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j ABBOTT LABORATORIES   (United States)

^k ELI LILLY AND COMPANY   (United States)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; ESTROGEN RECEPTOR; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BONE DENSITY; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; INTRADUCTAL CARCINOMA; ISCHEMIC HEART DISEASE; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SPINE FRACTURE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TUMOR INVASION;

EID: 84878107936     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60140-3     Document Type: Article

References (27)

1. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2: 282.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
3. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007; 7: 46-53.
4. Cuzick J, Powles T, Veronesi U., et al Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
5. Powles T, Eeles R, Ashley S., et al Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
6. Powles TJ, Ashley S, Tidy A., Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99: 283-90.
7. Cuzick J, Forbes J, Edwards R., et al, for the IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.
8. Cuzick J, Forbes JF, Sestak I, et al Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
9. Fisher B, Costantino JP, Wickerham D.L., et al Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-62.
11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97.
12. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007; 99: 727-37.
13. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-34.
14. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
15. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
16. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2727-41.
17. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010; 3: 696-706.
18. Cummings SR, Ensrud K, Delmas P.D., et al Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-96.
19. LaCroix AZ, Powles T, Osborne C.K., et al Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010; 102: 1706-15.
20. Cummings SR, McClung M, Reginster J.Y., et al Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2011; 26: 397-404.
21. Powles TJ, Diem SJ, Fabian C.J., et al Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat 2012; 134: 299-306.
22. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
24. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003; 163: 96-103.
25. Goss PE, Ingle JN, Ales-Martinez JE, et al Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-91.
26. Boyd NF, Guo H, Martin L.J., et al Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-36.
27. Evans DG, Warwick J, Astley S.M., et al Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res 2012; 5: 943-51.